echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > Hengrui pharmaceutical hydrochloric acid right metomide injection was evaluated by generic consistency

    Hengrui pharmaceutical hydrochloric acid right metomide injection was evaluated by generic consistency

    • Last Update: 2021-03-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    January 20, Hengrui Pharmaceuticals announced that recently received the State Drug Administration approved the issuance of the "drug supplement application approval notice" on hydrochloric acid right metomide injection, the company's hydrochloric acid right metomide injection through generic drug consistency evaluation.
    hydrochloric acid right metomy is a relatively selective alpha2-epinephrine-subjector agonist that is suitable for sedation during tracheal intination and mechanical ventilation in surgical patients undergoing general anaesthetic, sedation for patients who start intestion during intensive care and use a ventilator.
    hydrochloric acid right metomide injection was developed jointly by Oricon Pharma and Abbott and was first approved by the FDA in December 1999 under the name Precedex ®.
    follow-up in the European Union, Japan and other countries and regions listed for sale.
    Division I in 2009 took the lead in the domestic listing of hydrochloric acid right metomide injection, trademark for Abein ®, so far, in addition to the company, the domestic Sichuan Guorui, Hunan Colum, Yichang Renfu and other 11 enterprises have been approved for production, including Yangzijiang Pharmaceuticals, China Pharmaceutical Group Industry Co., Ltd. Langfang Branch 2 equivalent to through generic pharmaceutical consistency evaluation.
    other Zhengda Qing, Fu'an Pharmaceuticals and other declared production, did not see the approved information.
    the Evaluate Pharma database, the global sales of hydrochloric acid right metomide injections in 2019 are approximately $419 million.
    , the company has invested approximately RMB 6.79 million in research and development in the generics consistency evaluation project.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.